Kither Biotech
Alessandra Ghigo has a diverse work experience in the field of experimental biology. Alessandra started their career as a postdoctoral researcher at the Università degli Studi di Torino in January 2012 and worked there until September 2014. Following this, they served as an assistant professor of experimental biology from October 2014 to November 2016. Alessandra then held the role of tenured assistant professor in the same field from December 2016 to April 2020. Currently, they hold the position of associate professor of experimental biology since May 2020 at the same university.
In addition to their academic work, Alessandra Ghigo is actively involved in entrepreneurship. In July 2018, they co-founded and became a shareholder of the biotech company Kither Biotech. Alessandra also served on the company's board from July 2019 to February 2022.
During their career, Alessandra Ghigo also gained international experience by working as a visiting fellow at Université Paris-Sud from September 2008 to July 2009.
Alessandra Ghigo pursued their education at the Università degli Studi di Torino. From 2005 to 2007, they completed their Master's degree in Molecular Biotechnology at the university. Following this, they continued their education at the same institution and earned their Ph.D. in Oncology and Biomedical Sciences from 2007 to 2011. The specific field of study for both degrees is not provided.
This person is not in any teams
Kither Biotech
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.